

07.03.2022

12:25 - 13:00	Welcome to the ESMO Targeted Anticancer Therapies Congress (TAT) 2022 and Honorary award	Channel 1
	Moderation: R. Plummer ¹ , L. Siu ² , ¹ Newcastle University, Newcastle-upon-Tyne, GB, ² Princess Margaret Cancer Centre, Toronto, CA	
12:25 - 12:30	Live welcome to TAT 2022	
	<u>R. Plummer</u> ¹ , L. Siu ² , ¹ Newcastle University, Newcastle-upon-Tyne, GB, ² Princess Margaret Cancer Centre, Toronto, CA	
12:30 - 12:35	Introduction to the TAT 2022 Honorary award	
	<u>L. Siu</u> , Princess Margaret Cancer Centre, Toronto, CA	
12:35 - 13:00	The power of collaboration	
	<u>L. Seymour</u> , Canadian Cancer Trials Group, Kingston, CA	
13:00 - 14:00	Daiichi Sankyo/AstraZeneca - From bench to bedside and back to bench: The evolution of antibody-drug conjugates in the treatment of cancer	Channel 2
	Moderation: S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
13:00 - 13:10	Introduction	
	<u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
13:10 - 13:45	Round-table discussion (Recent developments in the ADC technology/application; Selection of target antigens; Identification of responders; Overcoming treatment resistance)	
	<u>M. Peipp</u> ¹ , A. Prat ² , S. Peters ³ , ¹ Christian-Albrechts-University Kiel, Kiel, DE, ² Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ³ CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
13:45 - 14:00	Q&A and closing remarks	
	<u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	

13:15 - 14:00	How reliable are the scientific data?	Channel 1
	Moderation: L. Ellis ¹ , E.G.E. De Vries ² , ¹ University of Texas MD Anderson Cancer Center, Houston, US, ² UMCG - University Medical Center Groningen, Groningen, NL	
13:15 - 13:35	Presentation	
	<u>E.G.E. De Vries</u> ¹ , L. Ellis ² , ¹ UMCG - University Medical Center Groningen, Groningen, NL, ² University of Texas MD Anderson Cancer Center, Houston, US	
13:35 - 14:00	Live Q&A and discussion	
14:15 - 15:30	Bispecifics and T-cell engagers	Channel 1
	Moderation: A. Greystoke ¹ , H. Van Der Vliet ² , ¹ The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ² Vrije University Medical Centre (VUMC), Amsterdam, NL	
14:15 - 14:35	Redirecting T-cells to kill cancer cells: Lessons learnt from CD3 BiTEs	
	<u>P. Baeuerle</u> , Cullinan Oncology, Cambridge, US	
14:35 - 14:55	Bispecific gamma-delta T-cell engagers for the treatment of cancer	
	<u>H. Van Der Vliet</u> , Vrije University Medical Centre (VUMC), Amsterdam, NL	
14:55 - 15:15	Targeting resistance-driving actionable mutations with bispecific antibodies	
	<u>J. Sabari</u> , NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US	
15:15 - 15:30	Live Q&A and discussion	

14:15 - 15:30	Molecular imaging for personalised medicine	Channel 2
	Moderation: E.G.E. De Vries ¹ , L. Siu ² , ¹ UMCG - University Medical Center Groningen, Groningen, NL, ² Princess Margaret Cancer Centre, Toronto, CA	
14:15 - 14:30	PET-based next generation molecular imaging	
	<u>A. Rominger</u> , University of Bern, Bern, CH	
14:30 - 14:45	PET/CT to select for and guide radioligand therapies	
	<u>M. Hofman</u> , Victorian Comprehensive Cancer Centre, Melbourne, AU	
14:45 - 15:00	Molecular imaging of immune checkpoints, immune cells and CAR-T cells for profiling tumour heterogeneity and selecting immunotherapy	
	<u>E.G.E. De Vries</u> , UMCG - University Medical Center Groningen, Groningen, NL	
15:00 - 15:15	Imaging therapeutic targets and drug engagement: Steroid receptors and PARP	
	<u>D. Mankoff</u> , Abramson Cancer Center - University of Pennsylvania, Philadelphia, US	
15:15 - 15:30	Live Q&A and discussion	
15:45 - 17:00	Cellular therapy beyond CART	Channel 1
	Moderation: J. Haanen ¹ , A. Stathis ² , ¹ Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, ² EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH	
15:45 - 16:00	Next generation genome editing for enabling allogeneic cell products	
	<u>Q. Waseem</u> , UCL Great Ormond Street Institute of Child Health, London, GB	
16:00 - 16:15	New developments in tumour infiltrating lymphocyte (TIL) therapy	
	<u>J. Haanen</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL	
16:15 - 16:30	T-cell receptor (TCRs)-based approaches to target solid tumours	
	<u>T. Blankenstein</u> , Max Delbrück Center for Molecular Medicine MDC, Berlin, DE	
16:30 - 16:45	Looking beyond T-cells: NK cells as effectors of tumour control	
	<u>U. Köhl</u> , Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, DE	
16:45 - 17:00	Live Q&A and discussion	

15:45 - 17:00	Early talent in early phase development	Channel 2
	Moderation: R. Plummer ¹ , L. Siu ² , ¹ Newcastle University, Newcastle-upon-Tyne, GB, ² Princess Margaret Cancer Centre, Toronto, CA	
15:45 - 16:00	Novel immunotherapies in breast cancer	
	<u>M. Kok</u> , Netherlands Cancer Institute, Amsterdam, NL	
16:00 - 16:15	Interventional studies on therapeutic microbiome manipulation	
	<u>A. Spreafico</u> , Princess Margaret Cancer Center, Toronto, CA	
16:15 - 16:30	Emerging combination strategies combining DDR and RT in NSCLC	
	<u>A. Greystoke</u> , The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB	
16:30 - 16:45	Breakthrough research combining ctDNA and computational biology	
	<u>I. Cortes-Ciriano</u> , EMBL-EBI - European Bioinformatics Institute, Hinxton, GB	
16:45 - 17:00	Live Q&A and discussion	
17:15 - 18:20	Mini Oral session	Channel 1
	Moderation: K. Dhingra ¹ , G. Shapiro ² , ¹ KAPital Consulting LLC,, New York, US, ² Dana Farber Cancer Institute, Boston, US	
17:15 - 17:20	5MO - Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase	
	<u>E. Fontana</u> ¹ , E. Lee ² , E. Rosen ³ , D. Spigel ⁴ , M. Højgaard ⁵ , S. Lheureux ⁶ , N. Mettu ⁷ , L. Carter ⁸ , R. Plummer ⁹ , P. Manley ⁶ , D. Ulanet ⁶ , V. Rimkunas ⁶ , I. Silverman ⁶ , J. O'Connell ⁶ , R. Mcdougall ⁶ , M. Wainszelbaum ⁶ , Y. Xu ⁶ , M. Koehler ⁶ , A. Fretland ⁶ , T. Yap ¹⁰ , ¹ Sarah Cannon Research Institute UK, London, GB, ² Dana-Farber Cancer Institute, Boston, US, ³ Memorial Sloan Kettering Cancer Center, New York, US, ⁴ Thoracic Medical Oncology, Nashville, US, ⁵ Department of Oncology, Copenhagen, DK, ⁶ Repare Therapeutics, Cambridge, US, ⁷ Medical Oncology, Durham, US, ⁸ Institution The Christie NHS Foundation Trust, Manchester, GB, ⁹ Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, ¹⁰ The University of Texas M. D. Anderson Cancer Center, Houston, US	
17:20 - 17:25	6MO - Translational relevance of the combined treatment PARP inhibitors and AsiDNA in homologous recombination proficient tumors	
	<u>W. Jdey</u> , V. Trochon-Joseph, C. Doizelet, V. Hayes, A. Cohendet, M.-C. Lienafa, C. Zandanel, O. De Beaumont, J. Miara, Onxeo, Paris, FR	
17:25 - 17:30	7MO - WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in small cell lung cancer	

T. Sen, Memorial Sloan Kettering Cancer Center, New York, US

17:30 - 17:40 **Invited Discussant of abstracts 5MO, 6MO and 7MO**

G. Shapiro, Dana Farber Cancer Institute, Boston, US

17:40 - 17:50 **Live Q&A and discussion**

17:50 - 17:55 **26MO - Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4**

S. Sun¹, A. Prelaj², C. Baik³, X. Le⁴, M. Garassino⁵, M. Wollner⁶, E. Haura⁷, Z. Piotrowska⁸, M. Socinski⁹, L. Dreiling¹⁰, G. Bhat¹⁰, F. Lebel¹⁰, R. Cornelissen¹¹, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ³Seattle Cancer Care Alliance, Seattle, US, ⁴UT MD Anderson Cancer Center, Houston, US, ⁵Istituto Nazionale dei Tumori di Milano- Fondazione IRCCS, Milan, IT, ⁶Rambam Healthcare Campus, Haifa, IL, ⁷H. Lee Moffitt Cancer Center & Research Institute, Tampa, US, ⁸Massachusetts General Hospital, Boston, US, ⁹Advent Health, Orlando, US, ¹⁰Spectrum Pharmaceuticals, Irvine, US, ¹¹Erasmus University Medical Center, Rotterdam, NL

17:55 - 18:00 **27MO - BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models**

M. Lucas¹, M. Merchant², M. O'Connor³, S. Smith², A. Trombino², W.-Y. Zhang², J. Simon², S. Eathiraj², N. Waters², E. Buck¹, ¹Black Diamond Therapeutics, New York, US, ²Black Diamond Therapeutics, Cambridge, US, ³Black Diamond Therapeutics, Stony Brook, US

18:00 - 18:10 **Invited Discussant of abstracts 26MO and 27MO**

K. Dhingra, KAPital Consulting LLC,, New York, US

18:10 - 18:20 **Live Q&A and discussion**

18:35 - 19:20	How to move forward an investigator initiated trial: Tips and tricks	Channel 2
	Moderation: T. Yap ¹ , R. Plummer ² , ¹ The University of Texas M. D. Anderson Cancer Center, Houston, US, ² Newcastle University, Newcastle-upon-Tyne, GB	
18:35 - 18:55	Presentation	
	<u>R. Plummer</u> ¹ , T. Yap ² , ¹ Newcastle University, Newcastle-upon-Tyne, GB, ² The University of Texas M. D. Anderson Cancer Center, Houston, US	
18:55 - 19:20	Live Q&A and discussion	
18:35 - 19:20	How to write a grant	Channel 1
	Moderation: J. De Bono ¹ , C. Yap ² , ¹ ICR - Institute of Cancer Research, London, GB, ² ICR - The Institute of Cancer Research - North Site, Sutton, GB	
18:35 - 18:55	Presentation	
	<u>J. De Bono</u> ¹ , C. Yap ² , ¹ ICR - Institute of Cancer Research, London, GB, ² ICR - The Institute of Cancer Research - North Site, Sutton, GB	
18:55 - 19:20	Live Q&A and discussion	
19:30 - 20:30	How to become an expert in early phase trials and drug discovery research	Lounge
	Moderation: T. Yap ¹ , M. Kok ² , R. Pihlak ³ , C. Oing ⁴ , ¹ The University of Texas M. D. Anderson Cancer Center, Houston, US, ² Netherlands Cancer Institute, Amsterdam, NL, ³ Manchester, GB, ⁴ Newcastle upon Tyne, DE	

08.03.2022

12:00 - 12:45 The industry perspective on optimal selection of drugs to take into the clinic Channel 2

Moderation: J. Lepin¹, M. Hellman², ¹ Thousand Oaks, US, ² Gaithersburg, US

12:00 - 12:20 **Presentation**

M. Hellman¹, J. Lepin², ¹ Gaithersburg, US, ² Thousand Oaks, US

12:20 - 12:45 **Live Q&A and discussion**

12:00 - 12:45 How to write, peer review and publish a manuscript Channel 1

Moderation: S. Bates¹, L. Seymour², ¹Columbia University, New York, US, ²Canadian Cancer Trials Group, Kingston, CA

12:00 - 12:20 **Presentation**

S. Bates¹, L. Seymour², ¹Columbia University, New York, US, ²Canadian Cancer Trials Group, Kingston, CA

12:20 - 12:45 **Live Q&A and discussion**

13:00 - 13:30 Keynote lecture Channel 1

Moderation: R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB

13:00 - 13:05 **Introduction to the Keynote lecture**

R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB

13:05 - 13:30 **Current clinical, molecular and immunological landscapes of breast cancer and future directions**

F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

13:45 - 15:00 Oral immuno-oncology agents Channel 2
Moderation: I. Melero¹, L. Zitvogel², ¹Clinica Universitaria de Navarra, Pamplona, ES,
²Institut Gustave Roussy, Villejuif, FR

13:45 - 14:00 **Acting on the prostaglandin pathway**
S. Zelenay, Cancer Research UK Manchester Institute, Manchester, GB

14:00 - 14:15 **Acting on the extracellular adenosine pathway**
I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

14:15 - 14:30 **Acting on gut microbiota**
L. Zitvogel, Institut Gustave Roussy, Villejuif, FR

14:30 - 14:45 **Small molecule drug discovery in immunotherapy**
R. Offringa, German Cancer Research Center, Heidelberg, DE

14:45 - 15:00 **Live Q&A and discussion**

13:45 - 15:00 Optimising kinase inhibitors Channel 1
Moderation: U. Banerji¹, E. Garralda², ¹The Institute of Cancer Research/Royal Marsden
NHS Foundation Trust, Sutton, GB, ²Vall d'Hebron University Hospital, Barcelona, ES

13:45 - 14:00 **The convergence of potency, selectivity and tumour biology: Inhibitors of NTRK, MET and RET**
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

14:00 - 14:15 **Broad spectrum and mutant-selective kinase inhibitor development for imatinib-resistant GIST**
S. Bauer, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

14:15 - 14:30 **Structural biology and precision targeting of RTK/RAS/MAPK inhibitors**
E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES

14:30 - 14:45 **Challenges in the development of brain-penetrant kinase inhibitors**
N. Steeghs, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:45 - 15:00 **Live Q&A and discussion**

15:15 - 16:30	COVID and drug development	Channel 2
	Moderation: E. Calvo ¹ , S. Postel-Vinay ² , ¹ Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ² Institut Gustave Roussy, Villejuif, FR	

15:15 - 15:30 **Trends in oncology clinical trials before and during the pandemic**
D. Araujo, Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, BR

15:30 - 15:45 **Early clinical trial management during the COVID-19 pandemic**
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

15:45 - 16:00 **COVID-19 pandemic: Impact on clinical trials and measures implemented to sustain activity**
A. Bayle, Hopital Europeen Georges-Pompidou - APHP, Paris, FR

16:00 - 16:15 **SARS-CoV-2 vaccination and cancer clinical trials**
U. Banerji, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

16:15 - 16:30 **Live Q&A and discussion**

15:15 - 16:30	Protein degradation	Channel 1
	Moderation: S. Alabi ¹ , P. Lorusso ² , ¹ Yale University, New Haven, US, ² Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US	

15:15 - 15:35 **Overview of protein degraders**
S. Alabi, Yale University, New Haven, US

15:35 - 15:55 **Protein degraders: Molecular mechanisms and therapeutic potential for targeting cancer**
A. Ciulli, University of Dundee, Dundee, GB

15:55 - 16:15 **Protein degraders: Therapeutic potential for solid tumour therapies**
A. Pandiella, Universidad de Salamanca (USAL) - 3 Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Salamanca, ES

16:15 - 16:30 **Live Q&A and discussion**

16:45 - 18:00 Patient selection for synthetic lethality trials Channel 2
Moderation: R. Plummer¹, T. Yap², ¹Newcastle University, Newcastle-upon-Tyne, GB,
²The University of Texas M. D. Anderson Cancer Center, Houston, US

16:45 - 17:00 **Patient selection for single agent ATRi in the clinic**
J. De Bono, ICR - Institute of Cancer Research, London, GB

17:00 - 17:15 **Exploiting PARP synthetic lethality beyond germline BRCA mutations**
J. Forment, Cambridge, GB

17:15 - 17:30 **Optimal dose, schedule and patient selection for ATRi and PARPi combinations**
M. Koehler, Repare Therapeutics, Cambridge, US

17:30 - 17:45 **Clinical activity of DNA PKi single agent and combination therapies**
A.H. Calvo, Princess Margaret Cancer Centre, Toronto, CA

17:45 - 18:00 **Live Q&A and discussion**

16:45 - 18:00 Antibody-drug conjugates (ADCs) Channel 1
Moderation: F. André¹, A. Bardia², ¹Gustave Roussy - Cancer Campus, Villejuif, FR,
²Massachusetts General Hospital Cancer Center, Boston, US

16:45 - 17:00 **Biochemical and physical principles of ADC structure**
P. Sapra, University of Alberta, New York, US

17:00 - 17:15 **Mechanisms of action of ADCs: Preclinical and clinical**
G. Montagnac, Institut Gustave Roussy, Villejuif, FR

17:15 - 17:30 **Current state of the art on ADC therapeutic strategies**
A. Bardia, Massachusetts General Hospital Cancer Center, Boston, US

17:30 - 17:45 **A glimpse to the future: Moving towards combinations**
J. Drago, Memorial Sloan Kettering Cancer Center, New York, US

17:45 - 18:00 **Live conclusions: Can we move towards personalised ADCs?**

18:15 - 18:35 Take home messages and close Channel 1

Moderation: R. Plummer¹, L. Siu², ¹Newcastle University, Newcastle-upon-Tyne, GB,
²Princess Margaret Cancer Centre, Toronto, CA

18:15 - 18:35 Live TAT 2022 highlights

A. Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH